Meta-Analysis

I have read the article entitled "With Increasing Use Of Meta-Analysis Come Efforts To Boost Validity" (S.P. Hoffert, The Scientist, Jan. 5, 1998, page 7) with some interest, and I would like to comment on a few points. Everybody likes to write and to publish positive results of clinical trials much more than negative results. Thus, it is the responsibility of the editors of biomedical journals to work against their own bias and ensure that results of so-called negative trials are published as

Written byHans-peter Adams
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

I have read the article entitled "With Increasing Use Of Meta-Analysis Come Efforts To Boost Validity" (S.P. Hoffert, The Scientist, Jan. 5, 1998, page 7) with some interest, and I would like to comment on a few points.

Everybody likes to write and to publish positive results of clinical trials much more than negative results. Thus, it is the responsibility of the editors of biomedical journals to work against their own bias and ensure that results of so-called negative trials are published as well (at least as a concise report). A properly designed and executed clinical trial has no negative or positive results, but one or more valid hypotheses are proven or rejected at a chosen level of significance with a given statistical power.

I fear a universal registry will be of no use unless all registered trials are peer reviewed, or certified, and adhere at least to good clinical ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies